Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Incyte Corporation : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 09:15am EST

The company will report its earnings for FY 2018 on 02/14/2019. Generally, the company reports earnings in line with the consensus. In recent months, the 15 analysts from Thomson Reuters consensus have revised their EPS estimates downward.

Annual earnings per share is expected at 0.41 USD for 2018 (- 126.8% from 2017). A summary of annual publications and estimates is available below.

Annual results2015201620172018 (e)2019 (e)
Sales
Million $
Released
Forecast
Spread

736
1 106
1 106
0,01%
1 536
1 518
1,2%



2 018
Operating income (EBITDA)
Million $
Released
Forecast
Spread
95,5
48,6
97%
203
199
2,1%
-192
-171
-12%

294

484
Operating profit (EBIT)
Million $
Released
Forecast
Spread
50,7
14,4
251%
145
118
23%
-244
-218
-12%

211

437
Pre-Tax Profit (EBT)
 
Released
Forecast
Spread










Net income
Million $
Released
Forecast
Spread

-34,7
101
120
-16%
-313
-236
-33%

100

292
EPS
 $
Released
Forecast
Spread
0,03
-0,19
116%
0,54
0,62
-13%
-1,53
-1,17
-31%

0,41

1,36
Announcement Date11/30/-000102/14/201702/15/2018

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INCYTE CORPORATION
02/14INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
AQ
02/14INCYTE : 4Q Earnings Snapshot
AQ
02/14INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
AQ
02/14INCYTE : Summary ToggleIncyte Reports 2018 Fourth Quarter and Year-End Financial..
PU
02/14INCYTE : Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 20..
BU
02/11INCYTE CORPORATION : annual earnings release
02/09INCYTE : FDA Extends Review Period for Ruxolitinib in GVHD
AQ
02/08INCYTE : Announces U.S. FDA Has Extended the Review Period for Ruxolitinib in Ac..
AQ
02/07INCYTE : Summary ToggleIncyte Announces U.S. FDA Has Extended the Review Period ..
PU
02/07INCYTE : Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jaka..
BU
More news
Financials ($)
Sales 2019 2 038 M
EBIT 2019 386 M
Net income 2019 277 M
Finance 2019 1 497 M
Yield 2019 -
P/E ratio 2019 73,73
P/E ratio 2020 41,61
EV / Sales 2019 8,05x
EV / Sales 2020 6,67x
Capitalization 17 908 M
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 88,7 $
Spread / Average Target 5,4%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Lothar H. Finke Head-Clinical Development & General Manager-Japan
Dashyant Dhanak Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION31.18%17 908
IQVIA HOLDINGS INC11.13%28 377
CELLTRION, INC.--.--%23 803
LONZA GROUP14.80%21 653
SEATTLE GENETICS, INC.17.42%11 477
EXACT SCIENCES CORPORATION39.65%10 883